U.K. warns against using arstolochia
This article was originally published in The Tan Sheet
Executive SummaryU.K. consumers should not use Xie Gan Wan pills, a Chinese product containing aristolochia, an unlicensed medicine the country banned in 1999, according to a Medicines and Healthcare products Regulatory Agency alert. MHRA identified a number of other products in recent years containing aristolochia, which can cause kidney failure. In 2004, California added aristolochic acid and other herbal remedies containing plant species of the genus aristolochia to the list of chemicals known to cause cancer (1"The Tan Sheet" July 12, 2004, In Brief)
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.